Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a Cancer and Leukemia Group B study

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2030-2037

  Ryan, Charles J ^a,e   Halabi, Susan ^b   Ou, San San ^b   Vogelzang, Nicholas J ^c   Kantoff, Philip ^d   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ANTIANDROGEN; HYDROCORTISONE; KETOCONAZOLE; PRASTERONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADRENAL GLAND; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; TISSUE LEVEL; TREATMENT OUTCOME;

ADRENAL GLANDS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; DRUG RESISTANCE, NEOPLASM; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34247523157     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2344     Document Type: Article

References (18)

1. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-50.
2. Feldman BJ, Feldman D. The development of androgen independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
3. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
4. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
5. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal. J Urol 1993; 149:607-9.
6. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22: 1025-33.
7. Labrie F, Belanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer: endocrine and biologic basis for its choice as new standard first-line therapy. Cancer 1993;71:1059.
8. Culig Z, Stober J, Gast A, et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect Prev 1996;20: 68-75.
9. Tan J, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-9.
10. Brendler H. Adrenalectomy and hypophysectomy for prostatic cancer. Urology 1973;2:99-102.
11. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 1994; 86:222-7.
12. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157:1204-7.
13. Harris K, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002;168:542-5.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
15. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7.
16. Hothorn T. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003; 43:121-37.
17. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11: 4653-7.
18. Trump DL, Havlin KH, Messing EM, et al. High-dose ketoconazole in advanced in hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 1989;7:1093-8.